Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Sutura Therapeutics Ltd.. (4/6/20). "Press Release: Sutura Therapeutics Appoints Alex Smith as Head of Patient Advocacy". Birkenhead.

Organisation Organisation Sutura Therapeutics Ltd.
Products Product gene therapy
  Product 2 gene transfer technology
Person Person Beards, Mark (Sutura Therapeutics 202004–CEO before Utility Therapeutics + Celixir + KPMG + Charles River Associates)

Sutura Therapeutics Limited has announced that Alex Smith has been appointed as Head of Patient Advocacy. To ensure that the company’s ‘Patient First’ ethos has real impact, Alex has also been appointed to the Board of Directors as an observer.

Alex has 10 years’ experience running the leading Duchenne Muscular Dystrophy charity Harrison’s Fund, since his eldest son was diagnosed with the fatal muscle wasting condition. He brings with him a wealth of experience working in a rare disease setting from a patient perspective, both in Europe and the U.S. He is a leading voice within the Duchenne community, representing patients at regulatory and advisory meetings at both the FDA and EMA.

“As a charity, Harrison’s Fund has worked with the team at Sutura and funded the development of their technology for five years, and I am thrilled to now be involved with the next stage of Sutura’s development. Together, we will take their ground-breaking technology out of the lab and into the hands of patients. The core value of ‘Patients First’ runs through the business, and I am delighted to be able to truly represent those values and the rare disease community in an advocacy capacity and at Board level” said Alex.

Mark Beards, CEO of Sutura commented, "We are privileged to welcome Alex to the team. He has tirelessly championed patients’ rights to have a key role in the decisions about their care, and he will bring this energy and clear perspective to Sutura as we move forward in our mission to pair compassionate beliefs with world-class research and drug delivery programmes.”

“I am thrilled to welcome Alex; he is driven to ensure best outcomes for both the Duchenne and the wider ‘rare-diseases’ communities. It is significant that his role includes working with the Board of Directors, giving a greater voice to those in most need and an honesty to all our clinical programs; Alex will be a true asset,” commented Keith Foster, Chief Scientific Officer of Sutura.

About Sutura Therapeutics Limited

Sutura Therapeutics Limited is a UK company developing novel, patent-protected gene medicines for multiple disease areas. The company has exclusive, worldwide rights to a delivery technology that is able to deliver gene medicines to any tissue.

Company Address

Sutura Therapeutics Limited
47 Hamilton Square
Birkenhead, Merseyside CH41 5AR
United Kingdom

Record changed: 2020-04-09


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Sutura Therapeutics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top